PerspectivePharmacology

“Inactive” ingredients in oral medications

See allHide authors and affiliations

Science Translational Medicine  13 Mar 2019:
Vol. 11, Issue 483, eaau6753
DOI: 10.1126/scitranslmed.aau6753

Article Information

vol. 11 no. 483

PubMed: 
Print ISSN: 
Online ISSN: 
History: 
  • Received for publication July 4, 2018
  • Accepted for publication February 22, 2019

Author Information

  1. Daniel Reker1,2,3,*,
  2. Steven M. Blum1,4,5,*,
  3. Christoph Steiger1,2,3,
  4. Kevin E. Anger4,
  5. Jamie M. Sommer6,
  6. John Fanikos6 and
  7. Giovanni Traverso1,2,3,4,7,
  1. 1Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.
  2. 2Division of Gastroenterology, Hepatology and Endoscopy, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA 02115, USA.
  3. 3MIT-IBM Watson AI Lab, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.
  4. 4Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA 02115, USA.
  5. 5Department of Medical Oncology, Dana-Farber Cancer Institute, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA 02115, USA.
  6. 6Investigational Drug Service, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA 02115, USA.
  7. 7Department of Mechanical Engineering, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.
  1. Corresponding author. Email: ctraverso{at}bwh.harvard.edu, cgt20{at}mit.edu
  • * These authors contributed equally to this work.

Altmetric

Article usage

Article usage: March 2019 to May 2019

AbstractFullPdf
Mar 2019163061341736
Apr 20198804686246
May 2019224015190